Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Evaluation of the clinical efficacy of the fluticasone-salmeterol fixed dose combination (FDC) in Greek patients with Chronic Obstructive Pulmonary Disease-AEOLOS study

Ioanna-Laoutselnta Markou, Stavros Tryfon, Paschalis Steiropoulos, Alexandros Ginis, Aikaterini Athanassiou, Nikolaos Grekas
European Respiratory Journal 2020 56: 3245; DOI: 10.1183/13993003.congress-2020.3245
Ioanna-Laoutselnta Markou
1Elpen Pharmaceutical Co. Inc., Pikermi, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: i.markou@elpen.gr
Stavros Tryfon
2G. Papanikolaou General Hospital, Thessaloniki, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paschalis Steiropoulos
3Univeristy Hospital of Alexandroupolis, Alexandroupolis, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandros Ginis
1Elpen Pharmaceutical Co. Inc., Pikermi, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aikaterini Athanassiou
1Elpen Pharmaceutical Co. Inc., Pikermi, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolaos Grekas
1Elpen Pharmaceutical Co. Inc., Pikermi, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 56 no. suppl 64
DOI 
https://doi.org/10.1183/13993003.congress-2020.3245

Published By 
European Respiratory Society
Print ISSN 
0903-1936
Online ISSN 
1399-3003
History 
  • Published online October 28, 2020.

Copyright & Usage 
Copyright ©the authors 2020

Author Information

  1. Ioanna-Laoutselnta Markou1⇑,
  2. Stavros Tryfon2,
  3. Paschalis Steiropoulos3,
  4. Alexandros Ginis1,
  5. Aikaterini Athanassiou1 and
  6. Nikolaos Grekas1
  1. 1Elpen Pharmaceutical Co. Inc., Pikermi, Greece
  2. 2G. Papanikolaou General Hospital, Thessaloniki, Greece
  3. 3Univeristy Hospital of Alexandroupolis, Alexandroupolis, Greece
  1. Ioanna-Laoutselnta Markou, Elpen Pharmaceutical Co. Inc., Pikermi, Greece. E-mail: i.markou{at}elpen.gr

Article usage

Article usage: October 2020 to May 2023

AbstractFullPdf
Oct 2020600
Nov 20205000
Dec 20209000
Jan 2021900
Feb 20211900
Mar 2021700
Apr 2021900
May 20212100
Jun 20212200
Jul 20212300
Aug 20211800
Sep 20212600
Oct 20212200
Nov 20212800
Dec 20211700
Jan 20222500
Feb 20222300
Mar 2022300
Apr 2022700
May 2022500
Jun 2022400
Jul 20221000
Aug 20221000
Sep 2022600
Oct 2022300
Nov 2022800
Dec 2022500
Jan 2023800
Feb 20231000
Mar 20231300
Apr 2023100
May 2023600

Altmetrics

Previous
Back to top
Vol 56 Issue suppl 64 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of the clinical efficacy of the fluticasone-salmeterol fixed dose combination (FDC) in Greek patients with Chronic Obstructive Pulmonary Disease-AEOLOS study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Evaluation of the clinical efficacy of the fluticasone-salmeterol fixed dose combination (FDC) in Greek patients with Chronic Obstructive Pulmonary Disease-AEOLOS study
Ioanna-Laoutselnta Markou, Stavros Tryfon, Paschalis Steiropoulos, Alexandros Ginis, Aikaterini Athanassiou, Nikolaos Grekas
European Respiratory Journal Sep 2020, 56 (suppl 64) 3245; DOI: 10.1183/13993003.congress-2020.3245

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Evaluation of the clinical efficacy of the fluticasone-salmeterol fixed dose combination (FDC) in Greek patients with Chronic Obstructive Pulmonary Disease-AEOLOS study
Ioanna-Laoutselnta Markou, Stavros Tryfon, Paschalis Steiropoulos, Alexandros Ginis, Aikaterini Athanassiou, Nikolaos Grekas
European Respiratory Journal Sep 2020, 56 (suppl 64) 3245; DOI: 10.1183/13993003.congress-2020.3245
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
  • Real-world Omalizumab and Mepolizumab treated Difficult Asthma Phenotypes and their Clinical Outcomes
  • Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
Show more Airway pharmacology and treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society